The veterinary antiparasitic that captured oncology's attention — mechanisms, studies, and the Joe Tippens protocol.
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Medical Disclaimer: Fenbendazole is NOT FDA-approved for human use. This page presents pre-clinical research and community anecdotes for educational purposes only. Nothing here constitutes medical advice. Do not use fenbendazole as a replacement for conventional cancer treatment. Consult your oncologist before considering any off-label compound.
Three simultaneous anticancer mechanisms identified in Dogra et al. (2018) and subsequent research
Fenbendazole binds tubulin and disrupts microtubule polymerization — the same mechanism as taxane chemotherapy agents. This halts cell division (mitotic arrest) and triggers apoptotic cell death, particularly in rapidly dividing cancer cells.
Cancer cells are heavily dependent on glucose via the Warburg effect. Fenbendazole downregulates GLUT4 glucose transporter expression and hexokinase activity, starving cancer cells of their preferred energy source while normal cells adapt more readily.
The p53 tumor suppressor gene is mutated or silenced in ~50% of human cancers. Fenbendazole has been shown to reactivate p53-mediated apoptosis pathways, potentially restoring a key natural defense against uncontrolled cell growth.
Unlike single-target agents, fenbendazole acts simultaneously on cytoskeletal integrity, metabolic pathways, and tumor suppression. This multi-pathway approach may reduce the likelihood of resistance development compared to single-mechanism drugs.
Evidence levels across cancer types — in vitro and animal model data only; no completed human trials
These are community-derived protocols — NOT clinical guidelines. Consult a physician before use.
Risk indicators based on available pre-clinical data and community reports
Peer-reviewed studies and clinical reports — pre-clinical unless noted
The landmark study. Demonstrates fenbendazole induces mitotic arrest and apoptosis in NSCLC cells via tubulin disruption, GLUT4 downregulation, and p53 pathway reactivation. Oral administration reduced tumor size in mouse xenograft models at doses tolerated without significant toxicity.
→ View on PubMed / DOIThe same research group found that combining fenbendazole with Vitamin E succinate (not tocopherol acetate) produced synergistic tumor suppression. This finding forms the rationale for including Vitamin E succinate specifically in community protocols.
→ Full PaperKorean research demonstrating fenbendazole retains activity against colorectal cancer cells resistant to 5-FU, a common chemotherapy agent. Suggests potential utility in chemo-resistant cancers and supports the multi-pathway mechanism hypothesis.
→ PubMedJoe Tippens, diagnosed with Stage 4 small cell lung cancer and given 3 months to live, claims complete remission after beginning a protocol including fenbendazole, Vitamin E succinate, curcumin, and CBD. His case has not been peer-reviewed and cannot be attributed solely to fenbendazole — but it launched global interest in the compound among cancer patients.
→ Joe Tippens' Site (mycancerstory.rocks)Community protocols typically include these alongside fenbendazole — affiliate links support MeetPeptide
Common questions about fenbendazole and cancer research
Explore similar compounds in the MeetPeptide database